 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Research Articles |
Alprostadil is a naturally occurring prostaglandin used in the treatment of infants with congenital heart defects to maintain the patency of the ductus arteriosus until palliative or corrective surgery can be performed. In infants with defects restricting pulmonary blood flow (cyanotic), alprostadil improves arterial blood oxygenation. In infants with defects restricting systemic blood flow, alprostadil improves arterial blood pH, urine output, and femoral arterial pulses. Alprostadil is administered by continuous intraarterial or intravenous infusion, usually at a starting dose of 0.1 microgram/kg/min, with maintenance doses as low as 0.002 microgram/kg/min. The most common side effects include fever, apnea, flushing, bradycardia, hypotension, and seizures; although in some cases, some of these effects may be related to the infant's underlying condition. Literature reports of clinical experience with alprostadil are reviewed.
This article has been cited by other articles:
|
|
 |
|
  G. D. Meckler and C. Lowe To Intubate or Not to Intubate? Transporting Infants on Prostaglandin E1 Pediatrics, January 1, 2009; 123(1): e25 - e30. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
